2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Apolipoprotein
  5. Apolipoprotein Isoform

Apolipoprotein

 

Apolipoprotein Related Products (54):

Cat. No. Product Name Effect Purity
  • HY-P2136
    COG1410
    		99.76%
    COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease.
  • HY-P1050A
    COG 133 TFA
    		99.89%
    COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM.
  • HY-P6306
    CS-6253
    		Agonist 98.84%
    CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease.
  • HY-122208
    SGA360
    		Inhibitor 99.93%
    SGA360 suppress inflammatory SAA1 signaling in an AHR-dependent manner through a mechanism that does not require AHR binding to its cognate response element (partial antagonist).
  • HY-W011824
    2′-O-Methyluridine
    		Inhibitor 99.92%
    2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer.
  • HY-108764B
    Mipomersen sodium scrambled negative control
    		Inhibitor 98.20%
    Mipomersen sodium scrambled negative control is the sequence scrambled negative control of Mipomersen sodium.
  • HY-151123C
    Pelacarsen sodium scrambled negative control
    Pelacarsen sodium scrambled negative control is the sequence scrambled negative control of Pelacarsen sodium.
  • HY-147425C
    Zerlasiran sodium scrambled negative control
    		Control
    Zerlasiran (SLN360) sodium scrambled negative control is the sequence scrambled negative control of Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
  • HY-132820
    Inaxaplin
    		Inhibitor 99.44%
    Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.
  • HY-P6365B
    APP-018
    		99.80%
    APP-018 (D-4F) is 18 D-amino acids peptide that mimics apolipoprotein A-I (apoA-I). APP-018 improves the anti-inflammatory activity of high-density lipoprotein (HDL). APP-018 can be used in researches of cardiovascular diseases.
  • HY-147425A
    Zerlasiran sodium
    		Inhibitor
    Zerlasiran (SLN360) sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
  • HY-111346
    1-Linoleoyl Glycerol
    		99.52%
    1-Linoleoyl glycerol is a LpPLA2 inhibitor. 1-Linoleoyl glycerol acts as a precursor for synthesizing various functional lipids, such as phospholipids. 1-Linoleoyl glycerol mitigates inflammation induced by Apolipoprotein CIII (reduction of IL-6).
  • HY-P99105
    Anselamimab
    		98.96%
    Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis.
  • HY-P6365
    APL180 TFA
    		98.69%
    APL180 TFA (L-4F) is an apolipoprotein AI mimetic peptide that enhances the anti-inflammatory activity of high-density lipoprotein (HDL). APL180 can be used in the study of cardiovascular diseases.
  • HY-143200
    OSBPL7-IN-1
    		Inhibitor 99.84%
    OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.
  • HY-151123A
    Pelacarsen sodium
    		98.67%
    Pelacarsen sodium (ISIS 681257 sodium) is a GalNAc3-conjugated 2′-MOE-modified antisense oligonucleotide. Pelacarsen sodium reduces apo (a).
  • HY-P6306A
    CS-6253 TFA
    		Agonist 98.53%
    CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease.
  • HY-141885
    APOL1-IN-1
    		Inhibitor 99.85%
    APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD).
  • HY-177653A
    Opemalirsen sodium
    		Inhibitor
    Opemalirsen sodium is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.
  • HY-145727C
    Volanesorsen scramble negative control
    		Control 98.82%
    Volanesorsen scramble negative control is a negative control for volanesorsen (HY-145727) with the sequence: CAUGUTCUTCUGCATGUCAU. Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that can lower triglyceride levels and improve insulin resistance.